The high and independent prediction accuracy of EuroFlow-NGF, for both OS and PFS, was recently demonstrated in a Spanish prospective study including more than 400 newly diagnosed MM patients; in this large cohort, only 7% of patients without a detectable disease (reported sensitivity of 10−6) relapsed, predominantly with extramedullary disease [127]. The gene discussed is NGF; the disease is Miyoshi myopathy.